Drug Patients (n ... In the treatment of rheumatoid arthritis, switching among biologic agents has become established practice when patients fail to achieve a response, lose response or experience ...

Rheumatoid arthritis (RA) is a chronic inflammatory disorder that primarily affects the joints, leading to pain and disability. The introduction of biologic drugs has significantly improved ...

Expert Rev Pharmacoeconomics Outcomes Res. 2012;12(3):319-333. The most recent biologic therapy to receive marketing approval, tocilizumab, was evaluated in a 24-week, randomized, placebo ...

Although sustained remission free of disease-modifying antirheumatic drugs “does not seem attainable” for patients with ...

Discover the reality behind Rheumatoid Arthritis, from its early onset potential to exercise benefits, backed by latest ...

Identify triggers, recognize symptoms, and manage RA flare-ups effectively with lifestyle, medication, and support for better ...

The "Biologics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global ...

A study from Spain found a subcutaneous tocilizumab biosimilar to be cost-effective when treating patients with rheumatoid ...

Alvotech and Teva announced FDA acceptance of the Biologics License Application (BLA) for AVT05, a proposed biosimilar ...

This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in ...

Five out of every 1,000 Malaysians are affected by Rheumatoid Arthritis (RA), a condition that causes chronic autoimmune ...